Russian Sarcoma Group

Ассоциация Специалистов по Изучению Сарком (rus)
Sarcoma Research Association in Russia

[National Comprehensive Cancer Network (NCCN) @NCCN]

The #NCCN2022 Annual Conference focuses on cancer patient journey; with cutting edge research and latest evidence-based care recommendations.
Learn more: https://t.co/nfUkvaF3KF

[Russian Sarcoma Group @SarcomaRus]

CLO22-087: Safety and Effectiveness of Continuous Denosumab for Unresectable or Advanced Giant Cell Tumor: Monthly and Once Every Three Months Regimen https://t.co/mSdNmIstgJ

[Everett Moding, MD, PhD @everettmoding]

Happy to share our data-driven review of circulating tumor DNA (#ctDNA) minimal residual disease (#MRD) in solid cancers now out in @CD_AACR. @Barzin_ @AshAlizadeh @max_diehn https://t.co/bwWvlC2Yod

[Sarcoma Cancer Ireland @SarcomaIreland]

Our online Sarcoma Ireland Support Group takes place this Tuesday, February 1st!

Please click the link below in order to receive a link for the session.

Hope to see you there 🌻💛

https://t.co/4RSPjinfux

[British Sarcoma Group @TheBSG_UK]

We've extended the early bird deadline to 11th Feb 2022 - register before this date to save money on your conference ticket! #sarcoma #bsg #welcometoliverpool #facetoface #medicalconferences

[Sandra P D'Angelo, MD @sandrapdangelo]

Dr. Klemen @nicholasklemen describes durable benefit of PD1 blockade in a subset patients w sarcoma, hyperprogression (HPD) occurred in 11% and no genomic predictors of response or HPD such as MDM2/EGFR. @MSKSarcoma @sloan_kettering
https://t.co/T1OkJ9CHbM

[EHE Foundation @EHEfoundation]

#EHE360 is underway! Dr. Stacchiotti @SilviaStacchia is giving an overview of the transformational EHE Consensus Paper from #ESMO. Jenni Kovach @iamjennikovach , #EHEfoundation President and Hugh Leonard, Chair of Trustees for @ehe_uk Thank you to sponsor: @IkenaOncology

[Ken Cardona @kencardonaMD]

Thoughtful take home points by @alegronchi.

[33rdEMSOS2020 @emsos2020]

More than 400 participants yesterday! 🎉Have a great day 2 at #emsos2021 https://t.co/mVWUEDnlEl

[Desmoid Tumor Research Foundation @DTRFoundation]

Every #clinicaltrial is hope.

🧬 In last 7 yrs, the # of trials for #desmoid patients is *equal* to the number of trials in the prior 23 yrs.

🧬 In last 8 yrs, an increase in phase II trials & the *1st* phase III trials for desmoid patients.

Give hope: https://t.co/ntvuS7ANFZ

[Patrick Schöffski @schoffski]

I now have two MDM2 inhibitors available in ongoing clinical trials in Leuven for patients with advanced dedifferentiated liposarcoma and select other mesenchymal and epithelial tumours with MDM2 amplification. Get in touch in case you have potential candidates!

[Russian Sarcoma Group @SarcomaRus]

О секции «Онкоортопедия» по гигантоклеточным опухолям в рамках XXV Российского онкологического конгресса. https://t.co/acignHTSwk @rutkowskip1972 @KisaySol #russco #rsg

[Anastasia Tararykova @KisaySol]

Outstanding and knowledgeable lecturer @rutkowskip1972 Thank you so much🙌🏻

[Russian Sarcoma Group @SarcomaRus]

We are pleased to announce that tomorrow will start Russian Sarcoma Meeting as part of XXV Annual Russian Oncology Society Congress with one of GCT management worldwide opinion leader @rutkowskip1972 #russco #rsg

[Russian Sarcoma Group @SarcomaRus]

ROLE OF 3D PRINTED IMPLANTS IN THE DEFECT RECONSTRUCTION IN PATIENTS WITH CHEST WALL TUMORS #CTOS2021 https://t.co/9ZzTPOCcyT

[Russian Sarcoma Group @SarcomaRus]

NEOADJUVANT DENOSUMAB IN GCT. LONG TERM INJECTION CAN DECREASE THE RISK OF LOCAL RECURRENCE #CTOS2021 https://t.co/xQyEGsa11K

[Russian Sarcoma Group @SarcomaRus]

ROLE OF MULTIDISCIPLINARY APPROACH IN A CASE OF SPINE OSTEOSARCOMA WITH OLIGOMETASTATIC HEART DISEASE #CTOS2021 https://t.co/YWSPwtTUG9

[Anastasia Tararykova @KisaySol]

Interesting notes after #ESMO2021 Could active surveillance for unresectable or metastatic chordoma be a feasible option? And how postop pathology in surgical LMS subgroup was correlated with PFS or OS in Dox+Trab arm? Huge thanks for all chairs and speakers #sarcoma

[Russian Sarcoma Group @SarcomaRus]

#ESMO2021 starts! #russiansarcomagroup #rsg #rsra

[Anastasia Tararykova @KisaySol]

Very interesting data about outcomes of different approach of CIC-rearranged sarcoma! And proving data of stay-and-look DF strategy in both great presentations, congratulations for all #ESMO2021 speakers

[Russian Sarcoma Group @SarcomaRus]

Dear friends, we are pleased to invite you to join the section of oncoorthopedics at the Innovative Oncology forum dedicated to the 70th anniversary of N.N. Blokhin NMRCO - the largest cancer center in Russia #russiansarcomagroup #rsg #rsra
https://t.co/1vIau5TGs5